Eli Lilly Arthritis Drug Baricitinib In Combination With Remdesivir Gets USFDA Okay To Treat Covid
New Delhi: The U.S. Food and Drug Administration on Thursday approved the emergency use of Eli Lilly and Co's arthritis drug, baricitinib, in combination with Gilead Sciences Inc's remdesivir, to treat COVID-19 patients.
Baricitinib, sold under the brand name of Olumiant, is an FDA-approved oral medication to treat moderately-to-severely active rheumatoid arthritis.
The approval was based on a review of the data from a clinical trial of hospitalized COVID-19 patients by the National Institute of Allergy and Infectious Diseases.
The trial showed an approximately one-day reduction in median recovery time for patients treated with the combination versus those treated with remdesivir.
Read also: Eli Lilly to acquire Disarm Therapeutics for USD 135 million
The health regulator approved the drug in combination with remdesivir for treating suspected or laboratory confirmed COVID-19 in hospitalized adults and children two years of age or older requiring oxygen support.
Read also: Eli Lilly neutralizing antibody gets USFDA emergency use authorization for Covid treatment
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!